1252124

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

November 22, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: *10/722,154*
FILING DATE: *November 25, 2003*
RELATED PCT APPLICATION NUMBER: *PCT/US04/34605*

Certified by

Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office

PTO/SB/05 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	010023-001100US
First Inventor	John H. Crowe, et al
Title	Method for Introducing...
Express Mail Label No.	EU122002615US

17497 U.S. PTO 10/722154 112503

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

1. ☑ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☑ Applicant claims small entity status. See 37 CFR 1.27.
3. ☑ Specification [*Total Pages* 29]
(preferred arrangement set forth below)
- Descriptive title of the invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings *(if filed)*
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

4. ☑ Drawing(s) (*35 U.S.C. 113*) [*Total Sheets* 7]
5. Oath or Declaration [*Total Sheets* _____]
a. ☐ Newly executed (original or copy)
b. ☐ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional with Box 18 completed)*
i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76
7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program *(Appendix)*
8. Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all necessary)*
a. ☐ Computer Readable Form (CRF)
b. Specification Sequence Listing on:
i. ☐ CD-ROM or CD-R (2 copies); or
ii. ☐ Paper
c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney *(when there is an assignee)*
11. ☐ English Translation Document *(if applicable)*
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☑ Return Receipt Postcard (MPEP 503) *(Should be specifically itemized)*
15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☑ Other: Express Mail Certificate.....

18. If a CONTINUING APPLICATION, *check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:*

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: .....

Prior application information: *Examiner* _____ *Art Unit:* _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☑ Customer Number: 37490 *OR* ☐ Correspondence address below

Name					
Address					
City		*State*		*Zip Code*	
Country		*Telephone*		*Fax*	

Name (Print/Type)	John W. Carpenter	*Registration No. (Attorney/Agent)*	26,447
Signature		*Date*	November 25, 2003

PTO/SB/17 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

	Complete If Known
Application Number	Unknown
Filing Date	November 25, 2003
First Named Inventor	John H. Crowe et al.
Examiner Name	Unknown
Group / Art Unit	Unknown
Attorney Docket No.	010023-001100

TOTAL AMOUNT OF PAYMENT ($) 430.00

METHOD OF PAYMENT (check one)

1. ☐ The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number:

Deposit Account Name:

☐ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Applicant claims small entity status. See 37 CFR 1.27

2. ☒ Payment Enclosed:

☒ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
101	770	201	385	Utility filing fee	385
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1) ($) 385.00

2. EXTRA CLAIM FEES

			Extra Claims		Fee from below		Fee Paid
Total Claims	25	-20	= 5	X	9	=	45
Independent Claims	3	-3	= 0	X	43	=	0
Multiple Dependent				X		=	0

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) ($) 45.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet.	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive – unavoidable	
141	1,280	241	640	Petition to revive – unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid SUBTOTAL (3) ($)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	John W. Carpenter	Registration No. (Attorney/Agent)	26,447	Telephone	650-842-0303
Signature				Date	November 25, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

In Re Application of: John H. Crowe, et al. **Application No.:** Unknown **Filing Date:** November 25, 2003 **Title:** METHOD FOR INTRODUCING MOLECULES INTO BIOLOGICAL SAMPLES	**Docket No.:** 010023-001100US **Re:** Filing Patent Application

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

EXPRESS MAIL CERTIFICATE

Utility Transmittal Letter;
Fee Transmittal Sheet;
Unsigned Declaration
Specification, Claims, Abstract and Drawings

I hereby certify that this paper and the enclosures listed above are being deposited with the U.S. Postal Service "Express Mail to Addressee" Express Mail No.: EU122002615US on November 25, 2003, and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: November 25, 2003

Respectfully submitted,

The Regents of the University of California

EU 122002615 US

By: _____
John W. Carpenter, Reg. No. 26,447
CARPENTER & KULAS, LLP
1900 Embarcadero Road
Suite 109
Palo Alto, CA 94303
USA

UC DAVIS 2004-067-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION FOR PATENT

METHOD FOR INTRODUCING MOLECULES INTO BIOLOGICAL SAMPLES

Inventors: John H. Crowe
Fern Tablin
Ann E. Oliver
Kamran Jamil
Joong-Hyuck Auh
Thurein Htoo
Willem Wolkers

Related Patent Applications

This patent application is related to co-pending patent application Serial No. 10/052,162, filed January 16, 2002. Patent application Serial No. 10/052,162 is a continuation-in-part patent application of co-pending patent application Serial No. 09/927,760, filed August 9, 2001. Patent application Serial No. 09/927,760 is a continuation-in-part patent application of co-pending patent application Serial No. 09/828,627, filed April 5, 2001. Patent application Serial No. 09/828,627 is a continuation patent application of patent application Serial No. 09/501,773, filed February 10, 2000.

Field of the Invention

Embodiments of the present invention generally broadly relate to biological samples, such as mammalian cells, platelets, and the like. More specifically, embodiments of the present invention generally provide for the preservation and survival of biological samples.

Embodiments of the present invention also generally broadly relate to the therapeutic uses of biological samples; more particularly to manipulations or modifications of biological samples, such as loading biological samples with solutes (e.g., carbohydrates, such as trehalose) and preparing dried compositions that can be re-hydrated at the time of application. When biological samples for various embodiments of the present invention are re-hydrated, they are immediately restored to viability.

The compositions and methods for embodiments of the present invention are useful in many applications, such as in medicine, pharmaceuticals, biotechnology, and agriculture, and including transfusion therapy, as hemostasis aids and for drug delivery.

Statement Regarding Federal Sponsored Research and Development

Embodiments of this invention were made with Government support under Grant No. N66001-03-1-8927, awarded by the Department of Defense Advanced Research Projects Agency (DARPA). Further embodiments of this invention were made with Government support under Grant Nos. HL57810 and HL61204, awarded by the National Institutes of Health. The Government has certain rights to embodiments of this invention.

Background of the Invention

A biological sample includes cells and blood platelets. A cell is typically broadly regarded in the art as a small, typically microscopic, mass of protoplasm bounded externally by a semi-permeable membrane, usually including one or more nuclei and various other organelles with their products. A cell is capable either alone or interacting with other cells of performing all the fundamental function(s) of life, and forming the smallest structural unit of living matter capable of functioning independently.

Cells may be transported and transplanted; however, this requires preservation which includes drying (e.g., vacuum drying, air drying, etc.), freezing and subsequent reconstitution (e.g., thawing, re-hydration, etc.) after transportation. Unfortunately, a very low percentage of cells retain their functionality after undergoing freezing and thawing. While some protectants, such as the cryoprotectant such as dimethylsulfoxide, tend to lessen the damage to cells, they still do not prevent some loss of cell functionality.

Blood platelets are typically generally oval to spherical in shape and have a diameter of 2-4 μm. Today platelet rich plasma concentrates are stored in blood bags at 22° C; however, the shelf life under these conditions is limited to five days. The rapid loss of platelet function during storage and risk of bacterial contamination complicates distribution and availability of platelet concentrates. Platelets tend to become activated at low temperatures. When activated they are

substantially useless for an application such as transfusion therapy. Therefore, the development of preservation methods that will increase platelet lifespan is desirable.

Trehalose has been found to be suitable in the preservation of cells and platelets. Trehalose is a disaccharide found at high concentrations in a wide variety of organisms that are capable of surviving almost complete dehydration. Trehalose has been shown to stabilize membranes, proteins, and certain cells and platelets during drying (e.g., freeze-drying) in vitro.

Spargo et al., U.S. Patent No. 5,736,313, issued April 7, 1998, have described a method in which platelets are loaded overnight with an agent, preferably glucose, and subsequently lyophilized. The platelets are preincubated in a buffer and then are loaded with carbohydrate, preferably glucose, having a concentration in the range of about 100 mM to about 1.5 M. The incubation is taught to be conducted at about 10°C to about 37°C, most preferably about 25° C.

U.S. Patent No. 5,827,741, Beattie et al., issued October 27, 1998, discloses cryoprotectants for human cells and platelets, such as dimethylsulfoxide and trehalose. The cells or platelets may be suspended, for example, in a solution containing a cryoprotectant at a temperature of about 22°C and then cooled to below 15°C. This incorporates some cryoprotectant into the cells or platelets, but not enough to prevent hemolysis of a large percentage of the cells or platlets.

Accordingly, a need exists for the effective and efficient preservation of biological samples, such as platelets and cells, and the like. More specifically, and accordingly further, a need also exists for the effective and efficient preservation of platelets and cells (e.g., erythrocytic cells, eukaryotic cells, or any other cells, and the like), such that the preserved platelets and cells respectively maintain their biological properties and may readily become viable after storage.

Summary of Embodiments of the Invention

Embodiments of the present invention provide a process for loading a biological sample comprising loading a biological sample with a solute (e.g., trehalose) by fluid phase endocytosis to produce an internally loaded biological sample. The loading of a biological sample by fluid phase endocytosis comprises fusing within the biological sample a first matter (e.g., a vesicle) with a second matter (a lysosome) to produce a fused matter. The fused matter preferably comprises the solute. The loading of a biological sample by fluid phase endocytosis additionally comprises transferring the solute from the fused matter into a cytoplasm within the biological sample. The fused matter may comprise a lower pH than a pH of the first matter. The fused matter preferably comprises a pH of less than about 6.5, such as from about 3.0 to about 6.0. The biological sample may include a biological sample selected from a group of biological samples comprising a platelet and a cell.

Embodiment of the present invention also provide a process for loading a solute into a biological sample comprising forming within a biological sample a vesicle having a solute, and lowering the pH of the vesicle to cause the biological sample to be loaded with the solute. The lowering of the pH of the vesicle comprises fusing the vesicle with a lysosome to produce fused matter. The lowering of the pH of the vesicle may also comprise increasing the permeability of a membrane in the biological sample for facilitating the passage of the solute from the vesicle into the biological sample. The fused matter preferably comprises a pH of less that about 6.5, such as from about 3.0 to about 6.0. A biological sample produced in

accordance with the foregoing process is also provided by embodiments of the present invention.

Embodiments of the present invention also further provide a process for preparing a dehydraded biological sample comprising providing a biological sample selected from a mammalian species, loading the biological sample with a solute by fluid phase endocytosis to produce a loaded biological sample, and drying (e.g., vacuum drying, air drying, freeze-drying, etc.) the loaded biological sample to produce a dehydrated biological sample.

These provisions together with the various ancillary provisions and features which will become apparent to those skilled in the art as the following description proceeds, are attained by the processes and biological samples (e.g., platelets, eukaryotic cells, and erythrocytic cells) of the present invention, preferred embodiments thereof being shown with reference to the accompanying drawings, by way of example only, wherein:

Brief Description of the Drawings

Figure 1 is an exemplary diagram of a biological sample having a plasma membrane with an internal protein coating and encapsulating a cytoplasm having lysosomes and a nucleus;

Figure 2 is an elevational view of the plasma membrane in contact with a solute solution having a solute which is to be loaded into the biological sample;

Figure 3 is an elevational view of the plasma membrane in the process of being loaded with a solute;

Figure 4 is an elevational view of a vesicle containing a solute and connected to the plasma membrane;

Figure 5 is a diagram of the cytoplasm having a lysosome and a vesicle containing a solute and which "budded off" or released from the plasma membrane;

Figure 6 is a diagram of a lysosome fused with a vesicle to produce fused matter or material containing a solute;

Figure 7 is a diagram of the fused matter or material containing a solute which is in the process of passing in direction of the arrow from the fused matter or material into the cytoplasm of the biological sample to effectively load the biological sample with the solute;

Figure 8 is an enlarged chemical structural, chain formula diagram of trehalose, a non-reducing disaccharide of glucose, with an arrow pointing to a glycosidic bond;

Figure 9 is an enlarged chemical structural, chain formula diagram of sucrose, a non-reducing disaccharide of glucose and fructose, with an arrow pointing to a glycosidic bond which is much more susceptible to hydrolysis than the glycosidic bond in trehalose;

Figure 10 is a graph of pH vs. % intact (i.e., % non-degraded) for trehalose and sucrose;

Figure 11 is a graph of % leakage of a fluorescent dye, carboxyfluorescein (CF), from phospholipid vesicles as a function of pH and time;

Figure 12 is a graph of rates of leakage (% leakage/10 minutes) as a function of pH;

Figure 13 is a graph of projected time to achieve 100% leakage, based on Figures 20 and 21, as a function of pH;

Figure 14 is a picture of control cells at zero (0) incubations time, showing no leakage of Lucifer yellow dye into the cytoplasm of the control cell;

Figure 15 is a picture of cells after 1 hour incubation time, showing Lucifer yellow dye in punctate structures (i.e., endocytotic vesicles) with some leakage of Lucifer yellow dye into the cytoplasm;

Figure 16 is a picture of cells after 3.5 hours incubation time, showing Lucifer yellow dye in punctuated structures (i.e., endocytotic vesicles) with more leakage of Lucifer yellow dye into the cytoplasm than the leakage represented in the picture of Figure 24; and

Figure 17 is a picture of cells after 5.0 hours incubation time, showing a uniform stain of Lucifer yellow dye which suggests that Lucifer yellow dye has leaked into the cytoplasm.

Detailed Description of Preferred Embodiments of the Invention

Embodiments of the present invention broadly include biological samples, preferably mammalian biological samples. Embodiments of the present invention further broadly include methods for preserving biological samples, as well as biological samples that have been manipulated (e.g., by drying to produce dehydrated biological samples) or modified (e.g., loaded with a chemical or drug) in accordance with methods of the present invention. Embodiments of the present invention also further broadly include methods for increasing the survival of biological samples, especially during drying and following drying, storing and rehydrating.

Biological samples for various embodiments of the present invention comprise any suitable biological sample, such as blood platelets and cells. The cells may be any type of cell including, not by way of limitation, erythrocytic cells, eukaryotic cells or any other cell, whether nucleated or non-nucleated.

The term "erythrocytic cell" is used to mean any red blood cell. Mammalian, particularly human, erythrocytes are preferred. Suitable mammalian species for providing erythrocytic cells include by way of example only, not only human, but also equine, canine, feline, or endangered species.

The term "eukaryotic cell" is used to mean any nucleated cell, i.e., a cell that possesses a nucleus surrounded by a

nuclear membrane, as well as any cell that is derived by terminal differentiation from a nucleated cell, even though the derived cell is not nucleated. Examples of the latter are terminally differentiated human red blood cells. Mammalian, and particularly human, eukaryotes are preferred. Suitable mammalian species include by way of example only, not only human, but also equine, canine, feline, or endangered species.

The source of the eukaryotic cells may be any suitable source such that the eukaryotic cells may be cultivated in accordance with well known procedures, such as incubating the eukaryotic cells with a suitable serum (e.g., fetal bovine serum). After the eukaryotic cells are cultured, they are subsequently harvested by any conventional procedure, such as by trypsinization, in order to be loaded with a protective preservative. The eukaryotic cells are preferably loaded by growing the eukaryotic cells in a liquid tissue culture medium. The preservative (e.g., an oligosaccharide, such as trehalose) is preferably dissolved in the liquid tissue culture medium, which includes any liquid solution capable of preserving living cells and tissue. Many types of mammalian tissue culture media are known in the literature and available from commercial suppliers, such as Sigma Chemical Company, St. Louis, Mo., USA: Aldrich Chemical Company, Inc., Milwaukee, Wis., USA; and Gibco BRL Life Technologies, Inc., Grand Island, N.Y., USA. Examples of media that are commercially available are Basal Medium Eagle, CRCM-30 Medium, CMRL Medium-1066, Dulbecco's Modified Eagle's Medium, Fischer's Medium, Glasgow Minimum Essential Medium, Ham's F-10 Medium, Ham's F-12 Medium, High Cell Density Medium, Iscove's Modified Dulbecco's Medium, Leibovitz's L-15 Medium, McCoy's 5A Medium (modified), Medium 199, Minimum Essential

Medium Eagle, Alpha Minimum Essential Medium, Earle's Minimum Essential Medium, Medium NCTC 109, Medium NCTC 135, RPMMI-1640 Medium, William's Medium E, Waymouth's MB 752/1 Medium, and Waymouth's MB 705/1 Medium.

Broadly, the preparation of solute-loaded biological sample(s) (e.g., platelets and cells) in accordance with embodiments of the invention comprises the steps of loading one or more biological samples with a solute by placing the biological samples in a solute solution for transferring by fluid phase endocytosis the solute from the solution into the biological sample(s). For increasing the transfer or uptake of the solute from the solute solution, the solute solution temperature, or incubation temperature, may have a temperature above about 25°C, more preferably above 30^0 C, such as from about 30^0 C to about 40^0 C.

The solute solution may be any suitable physiologically acceptable solution in an amount and under conditions effective to cause uptake or "introduction" of the solute from the solute solution into the biological sample(s) for fluid phase endocytosis. A physiologically acceptable solution is a suitable solute-loading buffer, such as any of the buffers stated in the previously mentioned related patent applications, all having been incorporated herein by reference thereto.

The solute is preferably a carbohydrate (e.g., an oligosaacharide) selected from the following groups of carbohydrates: a monosaccharide, an oligosaccharide (e.g., bioses, trioses, tetroses, pentoses, hexoses, heptoses, etc), a disaccharide (e.g., lactose, maltose, sucrose, melibiose,

trehalose, etc), a trisaccharide (e.g., raffinose, melezitose, etc), or tetrasaccharides (e.g., lupeose, stachyose, etc), and a polysaccharide (e.g., dextrins, starch groups, cellulose groups, etc). More preferably, the carbohydrate is a disaccharide, with trehalose being the preferred, particularly since it has been discovered that trehalose does not degrade or reduce in complexity upon being loaded. Thus, in the practice of various embodiments of the invention, trehalose is transferred from a solution into the biological sample without degradation of the trehalose.

Loading of the solute from the solute solution into the biological sample(s) broadly includes producing and/or forming at least a portion of a biological membrane of the microbiological sample(s) to entrap and include a solute; and fusing, commingling, or otherwise combining in any suitable manner, the produced and/or formed solute-containing portion of the biological membrane with a lysosome to produce fused matter from which the solute is transferred into the cytoplasm of the biological membrane (e.g., a cell). Producing and/or forming at least a portion of the biological membrane to include the solute comprises transferring or passing the solute from the solute solution against and/or into a portion of the biological membrane for producing and/or forming a vesicle (i.e., an endosomal, phagocytic vesicle) containing the solute. The vesicle after a period of time, which depends on the residence time of the biological sample in the solute solution, subsequently breaks or severs (i.e., "buds off") from the biological membrane into the cytoplasm of the biological sample(s) to fuse with lysosome(s).

The fusing or combining of the vesicle with a lysosome is caused by recognition sites on both membranes that promote fusion or the combining. The produced fused matter subsequently breaks down or degrades, with the lysosomal membranes being recycled and reloaded in the Golgi. Most sugars are degraded in the lysosome to monosaccharides, which are then transferred to the cytoplasm for further degradation. It is suggested that the mechanism of transfer includes the magnitude of the internal pH in the lysosomes which leads to leakage across the bilayers. The lysosome(s) has/have a low pH, such as a pH ranging from about from about 3.0 to about 5.0. In addition there is the presence of acidic hydrolases in the lysosomes. The vesicle, especially when the vesicle contains the solute, has a higher pH than the pH of the lysosome(s). The vesicle typically has a pH ranging from about 7.0 to about 8.0. Thus, the internal, engulfed material within the fused matter contains a reduced pH, a pH lower than the pH of the vesicle (e.g., a pH less than about 6.5, such as a pH ranging from about 3.5 to about 6.0).

The reduced pH, an acidic pH, causes the membrane of the produced fused matter to have an increased permeability. Stated alternatively, lowering the pH of the internal, engulfed material through the fusing of lysosome and vesicles produces an acidic engulfed material within the fused matter, which concomitantly raises or increases the permeability of the membrane of the fused matter. With an increase in permeability, the solute (or any low molecular weight molecules) leaks or passes through the membrane of the fused matter and into the cytoplasm.

When the solute is a sugar, most sugars hydrolyze within the fused matter. An exception is trehalose, which escapes degradation due to the stability of its associated glycosidic linkage. The broken down components of the lysosome and the vesicles are released into the cytoplasm for further metabolism. The components of sucrose would include glycose and fructose, which are degraded by the well known glycolytic pathway and the TCA cycle to CO_2 and H_2O. Because trehalose remains in tact for effecting the transferring and the loading of the solute into the cytoplasm of the biological sample(s), and does not degrade in conditions found in the lysome-endosome, trehalose is a preferred solute. However, it is to be understood that while trehalose is a preferred solute, the spirit and scope of the present invention includes any solute comprising one or more molecules that survive the environmental conditions within the fused matter. More specifically, the solute for various embodiments of the present invention comprises one or more of any molecule(s) that does not degrade under the transferring or loading conditions, or within the environmental conditions within the fused matter resulting from the fusing of lysosome and the vesicle. After the solute is transferred out of the fused matter and into the cytoplasm, stability is conferred on the biological sample for further treatment or processing, such as drying.

Referring now to Figures 1-7 for more specifically describing an embodiment of a mechanism for loading by fluid phase endocytosis a solute from a solute solution into a biological sample (e.g., platelet(s), cell(s), etc.), there is

seen in Figure 1 a biological sample **100** which is exemplarily represented as an intact cell **102** having a plasma membrane **104** internally coated with a protein (e.g., clathrin) **105**. The plasma membrane **104** encapsulates cytoplasm **108** having lysosomes **112**. The plasma membrane **104** may also encapsulate a nucleus **116** contained within the cytoplasm **108**.

The biological sample **100** is disposed in a solute solution **126** having a solute **T** (e.g., trehalose). As shown in Figure 2, the solute **T** is transferred or passed in direction of the arrow **A** from the solute solution **126** against and/or into a portion of the membrane **104**. As previously indicated, the solute solution **126** may be heated to an elevated temperature (e.g., a temperature from about 30^0 C to about 40^0 C) to assist in transferring the solute **T** out of the solute solution **126** and against and/or into a portion of the membrane **104**, causing the plasma membrane **104** including its associated protein coat **105** to bulge and/or concave inwardly (as best shown in Figure 3) to begin the formation of a portion of the membrane **104** having the solute **T**; that is, a vesicle **120** (see Figure 4) begins to form. Referring now to Figure 5 these is seen a partial plan view of the biological sample **100** after the subsequent release or "budding off" of the vesicle **120** into the cytoplasm **108**. The vesicle **120** is coated with the protein **105** and contains the solute **T**. As exemplarily shown in Figure 6, the vesicle **120** fuses with lysosome **112** to produce and/or form fused matter **124** which is also coated with the protein **105**.

The internal, engulfed material within the fused matter **124** contains a reduced pH (e.g., a pH ranging from about 3.5 to about 6.0) due to ion pumps in the membrane. The acid hydrolases are activated by the low pH. The reduced pH of the internal, engulfed material causes the outer skin or membrane of the produced fused matter **124** to have an increased permeability which facilitates the leakage or passage of the solute (or any low molecular weight molecules) through the outer skin or membrane of the fused matter **124**, as illustrated in Figure 7. As previously indicated, when the solute is trehalose or any other low molecular weight molecule that is immune to the acidic engulfed material within the fused matter **124**, trehalose escapes degradation due to the stability of its associated glycosidal linkage and freely passes intact through the increased-permeability membrane of the fused matter. As previously suggested, the remaining broken down components of the lysosome and the vesicle are released into the cytoplasm for further metabolism. Thus, the solute **T** is transferred out of the fused matter **124**, as represented by arrow **B** in Figure 7, when the permeability of the membrane of the fussed matter **124** is increased, and when the engulfed material within the fused matter **124** breaks down or degrades for further metabolism within the cytoplasm. As previously indicated, the solute **T** preferably remains intact during the loading and/or solute transferring process and within the internal environment of the fused matter **124**. Thus, the solute **T** remains essentially intact and whole when transferred out of the fused matter **124** and into the cytoplasm **108**. The solute **T** survives conditions found in the lysosome-endosome and the intact solute **T** leaks through the outer membrane of the fused matter **124** and into the cytoplasm.

The biological sample **100** is now ready for further processing, such as drying, freezing, and subsequent rehydration, etc.

A preferred solute for embodiments of the present invention comprises trehalose. Most sugars degrade in fused lysosome-endosome due to the reduced pH and presence of acid hydrolases. Trehalose is the only non-reducing disaccharide of glusose. Figure 8 is an enlarged chemical structural, chain formula diagram of trehalose, a non-reducing disaccharide of glucose, with an arrow pointing to a glycosidic bond. Severing of the glycosidic bond produces glucose which is ineffective in stabilizing dry biological materials. Sucrose, on the other hand, is a non-reducing disaccharide of glucose and fructose. Figure 9 is an enlarged chemical structural, chain formula diagram of sucrose, a non-reducing disaccharide of glucose and fructose, with an arrow pointing to a glycosidic bond which is much more susceptible to hydrolysis than the glycosidic bond in trehalose. Trehalose survives conditions found in the lysosome-endosome and intact trehalose leaks into the cytosol of living cells.

Referring now to Figure 10, there is seen a graph of pH vs. % intact (i.e., % non-degraded) for trehalose and sucrose. Trehalose survives survival (i.e., remains 100 % intact) down to a pH 1, while sucrose hydrolyzes into glucose and fructose at pH as 5. The % of intact sucrose commences to decrease below a pH of about 6. Thus, sucrose begins to break down at a pH below 6. Example 1 below provides the more specific testing conditions and parameters which produced the graphical, illustrations of Figure 10.

Figure 11 is a graph of % leakage of a fluorescent dye, carboxyfluorescein (CF), from phospholipid vesicles as a function of pH and time. As the pH decreases from about 7.0 to a pH of about 3.0 and as time increases (e.g., increases from about 0 to about 20 minutes, the % leakage of the fluorescent dye increases. There is little or no leakage at a pH of about 7.0 or above, but leakage proceeds rapidly at a pH below about 5.0. At pH of about 3.0, 100 % of the solute leaked out in 20 minutes. Thus, the leakage of the fluorescent dye CF from liposomes increases with pH and time.

With respect to rate of leakage and the time for leakage, the rate of leakage increases as the pH decreases, as best illustrated in Figure 12, and the time to achieve 100 % leak increases with increase in pH, as best shown in Figure 13. Figure 12 is a graph of rates of leakage (% leakage/10 minutes) as a function of pH. At pH of 3-4 leakage goes to completion in 20-30 minutes, while at pH 7, three months would be required to complete the leakage. Figure 13 is a graph of projected time to achieve 100% leakage, based on Figures 11 and 12, as a function of pH. The time to achieve 100 % depletion especially increases after a pH of 5. Example 2 below provides the more specific testing conditions and parameters which produced the graphical, illustrations of Figures 11-13.

Referring now to Figures 14-17, there is seen a distribution of Lucifer yellow in intact cells as a function of incubation time. More specifically, Figure 14 is a picture of control cells at zero (0) incubation time, showing no leakage of Lucifer yellow dye into the cytoplasm of the control cell. Figure 15 is a picture of cells after 1 hour incubation time, showing Lucifer yellow dye in punctate structures (i.e.,

endocytotic vesicles) with some leakage of Lucifer yellow dye into the cytoplasm. Figure 16 is a picture of cells after 3.5 hours incubation time, showing Lucifer yellow dye in punctate structures (i.e., endocytotic vesicles) with more leakage of Lucifer yellow dye into the cytoplasm than the leakage represented in the picture of Figure 15; and Figure 17 is a picture of cells after 5.0 hours incubation time, showing a uniform stain of Lucifer yellow dye which suggests that Lucifer yellow dye has leaked into the cytoplasm. Example 3 below provides the more specific testing conditions and parameters which produced the graphical, illustrations of Figures 14-17. At short incubation times (e.g., incubation times of 1 hour and 3.5 hours), the dye is in punctate structures. With long incubation time (e.g., 5 hours) the staining becomes uniform, suggesting that the dye has leaked into the cytoplasm. Example 3 below provides the more specific testing conditions and parameters which produced the graphical, illustrations of Figures 14-17.

Embodiments of the present invention will be illustrated by the following set forth examples which are being given by way of illustration only and not by way of any limitation. It is to be understood that all materials, chemical compositions and procedures referred to below, but not explained, are well documented in published literature and known to those artisans possessing skill in the art.

All materials and chemical compositions whose source(s) are not stated below are readily available from commercial suppliers, who are also known to those artisans possessing skill in the art. All parameters such as concentrations, mixing proportions, temperatures, rates, compounds, etc., submitted in

these examples are not to be construed to unduly limit the scope of the invention.

EXAMPLE 1

Trehalose and sucrose solutions were prepared in water (100 mM). The solutions were heated to 70^0 C for 30 minutes, after which the solutions were analyzed by HPLC (high performance liquid chromatograph). Trehalose survived this treatement down to pH 1.0, while most of the sucrose was hydrolyzed to glucose and fructose at pH as high as 5. At lower temperatures this pattern persisted, although the time required to hydrolyze the sucrose increased. It is well established that the pH in lysosomes is 4-5, so it follows that sucrose if likely to be degraded in lysosomes, while trehalose should escape damage. The residence time in the lysosomes would be expected to be critical in this regard. At 37^0 C, for example, sucrose would experience minimal degradation if the residence time is 10 minutes, but degradation would be extensive if the residence time were on the order of hours.

EXAMPLE 2

Membranes become leaky at the pH found in lysosomes. Liposomes composed of the phospholipids POPC (palmitoyloleyoylphosphatidylcholine) and PS (phosphatidylserine) (9:1) were prepared by extrusion through 100 nm filters. A marker for permeability, the fluorescent marker carboxyfluorescein (CF) was trapped in liposomes at a

concentration of 0.5 M during the extrusion. External CF was removed by passing the liposomes through a Sephadex column. The liposomes were then subjected to decreased pH. CF is fluorescent, but self-quenching at the concentration at which it was trapped in the lipsosomes. When the trapped CF leaks into the external medium, it becomes diluted, and fluorescence increases. From the rate of increase in fluorescence it is possible to deduce the permeability.

EXAMPLE 3

Leakage from lysosomes *in vivo* is in reasonable agreement with the *in vitro* data. Cells were incubated in a fluorescent probe, Lucifer yellow. This particular probe was chosen as a tracer since it is approximately the same size as a disaccharide. The cells were washed free of extracellular Lucifer yellow and then observed by fluorescence microscopy. The results are shown in Figures 14-17. When the cells were incubated in the dye for 1 to 3.5 hours, punctuate staining was clearly seen, indicating the presence of the dye in endosomes or lysosomes. However, by 5 hours much of the punctuate staining disappeared and the cytoplasm acquired a uniform fluorescence. Thus, 3.5 to 5 hours are required for appreciable leakage to occur. Thus, there is reasonable agreement between the two measurements.

EXAMPLE 4

Trehalose survives passage through lysosomes in vivo, while other sugars do not. Platelet cells were incubated for four hours in 100 mM trehalose, sucrose, or raffinose, respectively. The platelet cells were then homogenized in 60 % methanol, from which the large particles were pelleted by centrifugation. The supernatant was removed, and analyzed by HPLC. The results showed that trehalose was recovered intact, with no evidence of degradation. Raffinose appeared to be completely hydrolyzed. Sucrose was partially hydrolyzed, but significant amounts of intact sucrose were obtained, nevertheless. It may well be that the difference between raffinose and sucrose lies in the fact that raffinose is a trisaccharide and thus might be expected to leak across the lysosomal membrane more slowly than does sucrose. Thus, with increased residence time hydrolysis would go further towards completion. Even a small amount of hydrolysis might not be acceptable; the monosaccharides that are produced as a result of the hydrolysis are all reducing sugars, and all show the Maillard reaction with dry proteins, a reaction that denatures the protein irreversibly.

Conclusion

Embodiments of the present invention provide that trehalose, a sugar found at high concentrations in organisms that normally survive dehydration, can be used to preserve biological structures in the dry state. Human biological sample(s) can be loaded with trehalose under specified

conditions, and the loaded biological sample(s) can be dried (e.g., freeze dried) with excellent recovery.

While the present invention has been described herein with reference to particular embodiments thereof, a latitude of modification, various changes and substitutions are intended in the foregoing disclosure, and it will be appreciated that in some instances some features of the invention will be employed without a corresponding use of other features without departing from the scope and spirit of the invention as set forth. Therefore, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope and spirit of the present invention. It is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments and equivalents falling within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A process for loading a biological sample comprising; loading a biological sample with a solute by fluid phase endocytosis to produce an internally loaded biological sample.

2. The process of Claim 1 wherein said loading a biological sample by fluid phase endocytosis comprises fusing within the biological sample a first matter with a second matter to produce a fused matter.

3. The process of Claim 2 wherein said first matter comprises the solute.

4. The process of Claim 2 wherein said first matter comprises a vesicle having the solute.

5. The process of Claim 2 wherein said second matter comprises a lysosome.

6. The process of Claim 4 wherein said second matter comprises a lysosome.

7. The process of Claim 2 wherein said fused matter comprises the solute.

8. The process of Claim 6 wherein said fused matter comprises the solute.

9. The process of Claim 2 wherein said loading a biological sample by fluid phase

endocytosis additionally comprises transferring the solute from the fused matter within the biological sample.

10. The process of Claim 8 wherein said loading a biological sample by fluid phase endocytosis additionally comprises transferring the solute from the fused matter within the biological sample.

11. The process of Claim 9 wherein the solute is transferred from the fused matter into a cytoplasm within the biological sample.

12. The process of Claim 10 wherein the solute is transferred from the fused matter into a cytoplasm within the biological sample.

13. The process of Claim 2 wherein said fused matter comprises a lower pH than a pH of the first matter.

14. The process of Claim 12 wherein said fused matter comprises a lower pH than a pH of the first matter.

15. The process of Claim 2 wherein said fused matter comprises a pH of less than about 6.5.

16. The process of Claim 1 wherein said biological sample includes a biological sample selected from a group of biological samples comprising a platelet and a cell.

17. The process of Claim 1 wherein said solute comprises trehalose.

18. A biological sample produced in accordance with the process of Claim 1.

19. A process for preparing a dehydrated biological sample comprising:

providing a biological sample selected from a mammalian species;

loading the biological sample with a solute by fluid phase endocytosis to produce a loaded biological sample; and

drying the loaded biological sample to produce a dehydrated biological sample.

20. The process of Claim 19 wherein said loading of the biological sample with a solute comprises loading of the biological sample with an oligosaccharide from an oligosaccharide solution.

21. A process for loading a solute into a biological sample comprising:

forming within a biological sample a vesicle having a solute; and

lowering the pH of the vesicle to cause the biological sample to be loaded with the solute.

22. The process of Claim 21 wherein said lowering of the pH of the vesicle comprises fusing the vesicle with a lysosome to produce fused matter.

23. The process of Claim 21 wherein said lowering of the pH of the vesicle comprises increasing the permeability of a membrane in the biological sample for facilitating the passage of the solute from the vesicle into the biological sample.

24. The process of Claim 22 wherein said fused matter comprises a pH of less that about 6.5.

25. A biological sample produced in accordance with the process of Claim 21.

ABSTRACT OF THE DISCLOSURE

A method for loading a biological sample comprising loading a biological sample with a solute by fluid phase endocytosis to produce an internally loaded biological sample. Within the biological sample a first matter (e.g., a vesicle) having the solute fuses with a second matter (e.g., a lysosome) to produce a fused matter containing the solute. Loading of the biological sample includes transferring the solute from the fused matter into cytoplasm within the biological sample.



Figure 1



Figure 2

Figure 3



Figure 4



Figure 7

Figure 6



Figure 5

mechanism for loading trehalose into cells



Fig 8



Figure 9



Figure 10



Figure 11



Figure 12



Figure 13.

0 hrs (control)

Figure 14

1 hr

Figure 15

3.5 hrs

Figure 16



5 hrs

Figure 17

PATENT

Applicant: John H. Crowe et al.
Serial No.: Unknown
Filed:
Title: Method for Introducing Molecules into Biological Samples

Group: Unknown
Examiner; Unknown
Docket No. 010023-001100

COMBINED DECLARATION AND POWER OF ATTORNEY
[ORIGINAL, DESIGN, SUPPLEMENTAL, NATIONAL STAGE OFPCT, DIVISIONAL, CONTINUATION OR *CONTINUATION-IN-PART]*

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is of the following type:

☒ original (regular)

☐ design

☐ supplemental-continuation of PCT Application in the U.S.

NOTE: If the declaration is for an International Application being filed as a divisional; continuation, or continuation-in-part, do not check the next item; check appropriate one of last three items.

☐ national stage of PCT divisional continuation continuation-in-part

INVENTORSHIP IDENTIFICATION

WARNING: If the inventors are each not the inventors of all of the claims, an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.

My residence, post office address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention described in

SPECIFICATION IDENTIFICATION

☒ the specification filed herewith by the above-named inventors, with the title listed above.

☐ the specification filed herewith by the above-named inventors, with the title listed above, and which was amended by the Preliminary Amendment filed herewith.

☐ the specification identified above, as amended by the Preliminary Amendment filed herewith.

☐ the specification identified above, Serial No._____ filed on_____.

☐ PCT International Application No. _____ filed on _____, and amended under PCT Article 19 on_____(if applicable).

Attorney Docket No.: 010023-001100

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. §1.56.

PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))

I hereby claim foreign priority benefits under 35 U.S.C. §§ 11 9(a)-(d) of any foreign application(s) for patent or inventor's certificate or under 35 U.S.C. § 365(b) of any PCT international application(s) designating at least one country other than the United States of America listed below, and have also identified below any foreign application(s) or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

☐ No such applications have been filed.

☐ Such applications have been filed as follows:

PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THISAPPLICATION AND ANY PRIORITY CLAIMS UNDER 35 U.S.C.§ 119(a)-(d)

COUNTRY (or indicate if PCT)	APPLICATION NUMBER	FILING DATE	PRIORITY CLAIMED UNDER 37 U.S.C. §119	
			☐ YES	☐ NO
			☐ YES	☐ NO
			☐ YES	☐ NO
			☐ YES	☐ NO

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (35 U.S.C. § 119(e))

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional applications(s) listed below:

PROVISIONAL APPLICATION SERIAL NUMBER	FILING DATE OF PROVISIONAL APPLICA TION

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S) UNDER 35 U.S.120

(Complete this part only if this is a divisional, continuation, CIP or national stage of PCT.)

I/We hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/ are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability under 37 C.F.R. § 1.56, which occurred between the filing date of the prior application(s) and the national or PCT international filling date of this application.

Attorney Docket No.: 010023-001100

PRIOR U.S. PROVISIONAL APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. § 120:

1. U.S. Applications:

SERIAL NUMBER	FILING DATE

2. PCT Applications Designating The U.S.

PCT APPLICATION NUMBER	PCTFILING DATE	U.S. SERIAL NUMBER

POWER OF ATTORNEY

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

John W. Carpenter	26,447
Charles J. Kulas	35,809

☐ Attached as part of this declaration and power of attorney is the authorization of the above-named attorney to accept and follow instructions from my representative(s).

SEND CORRESPONDENCE TO:

Carpenter & Kulas, LLP
1900 Embarcadero Road, Suite 109
Palo Alto, CA 94303

DIRECT TELEPHONE CALLS TO:

John W. Carpenter
(650) 842-0303

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code,, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Attorney Docket No.: 010023-001100
SIGNATURE(S)
Full name of first inventor: John H. Crowe

Inventor's
Signature: _____

Date: _____ Country of Citizenship: USA

Residence: 1111 Cottonwood Court, Davis, CA 95616

P.O. Address: same

Full name of second inventor: Fern Tablin

Inventor's
Signature: _____

Date: _____ Country of Citizenship: USA

Residence: 608 Huble Street, Davis, CA 95616

P.O. Address: same

Full name of third inventor: Willem Wolkers

Inventor's
Signature: _____

Date: _____ Country of Citizenship: The Netherlands

Residence: 607 East 8th Street, Apt. 5A, Davis, CA 95616

P.O. Address: same

Full name of fourth inventor: Ann E. Oliver

Inventor's
Signature: _____

Date: _____ Country of Citizenship: USA

Residence: 874 Parklin Avenue, Sacramento, CA 95831

P.O. Address: same

Full name of fifth inventor: Kamran Jamil

Inventor's
Signature: _____

Date: _____ Country of Citizenship: USA

Residence: 33 W. Elliot Street, #50, Woodland Hills, CA 95695

P.O. Address: same

Attorney Docket No.: 010023-001100

Full name of sixth inventor: Joong-Hyuck Auh

Inventor's
Signature:_____

Date:_____ Country of Citizenship: Korea

Residence: 4005 Cowell Blvd., #807, Davis, CA 95616

P.O. Address: same

Full name of seventh inventor: Thurein Htoo

Inventor's
Signature:_____

Date:_____ Country of Citizenship: USA

Residence: 212 Conant Road, Apt. D, Rochester, NY 14623

P.O. Address: same

CHECK PROPER BOX(ES) FOR ANY OF THE FOLLOWING ADDED P AGE(S) \VHICH FORM A P ART OF THIS DECLARATION

☒ Signature for third and subsequent joint inventors.
Number of pages added 1

☐ Signature by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor.
Number of pages added _____.

☐ Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47.
Number of pages added _____.

☐ Signature by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time under 37 CFR 1.47.
Number of pages added _____.

☐ Authorization of attorney(s) to accept and follow instructions from representative.

☒ This Declaration ends with this page.

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/034605

International filing date: 18 October 2004 (18.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 10/722,154
Filing date: 25 November 2003 (25.11.2003)

Date of receipt at the International Bureau: 26 November 2004 (26.11.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse